Devanand Sarkar and a team of scientists at VCU Massey Comprehensive Cancer Center found that TAF2 is overexpressed in hepatocellular carcinoma patients compared to individuals with healthy livers. Through preclinical research, they discovered that TAF2 regulates the survival of hepatocytes—the functional cells of the liver—and tumor formation. Their study—recently published in the journal Hepatology—also demonstrates that TAF2 cooperates with the MYC gene, another known major driver of cancer, to accelerate tumor growth.

A groundbreaking new review comprehensively synthesizes the latest developments in next-generation chimeric antigen receptor T cell (CAR-T) therapies, highlighting key preclinical and clinical breakthroughs in the treatment of lymphoma. The article examines barriers to CAR-T efficacy and provides an in-depth analysis of innovative strategies, including multi-specific CAR, T cells redirected for universal cytokine-mediated killing (TRUCKs), switch receptor CAR, safety switch/suicide system, and in vivo CAR-T cells. With a special focus on the role of epigenetics and metabolism in CAR-T cell exhaustion, the review offers valuable insights and future directions for advancing CAR-T immunotherapy.

 Bispecific antibodies (bsAbs) refer to antibodies that bind two different antigens or epitopes simultaneously, which can enhance the targeting of antibodies and the efficacy of cancer treatments. Recent studies indicate that bsAb is a promising first-line or later-line treatment for non-small cell lung cancer (NSCLC) patients and may overcome treatment resistance. This study explores the classification, mechanisms of action and clinical application of bsAbs in the treatment of NSCLC.